BLA Submitted for OctaplasLG for Adverse Transfusion Events

Octapharma announced that it has submitted a Biological License Application (BLA) to the FDA for octaplasLG for managing preoperative or bleeding patients who require replacement of multiple plasma coagulation factors. The application also seeks to gain marketing approval for the substitution of intentionally removed plasma, such as plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP), a blood disorder that causes clot formation in small blood vessels.

OctaplasLG is a solvent/detergent treated human plasma solution.

For more information, call (888) 429-4535 or visit